LCZ 696 (Entresto) API Market

The LCZ 696 (Entresto) API market is projected to grow at a CAGR of 7.2% from 2025 to 2035, driven by the rising prevalence of heart failure globally and increased adoption of advanced cardiovascular therapies. LCZ 696 is the active pharmaceutical ingredient in Entresto, a novel fixed-dose combination of sacubitril and valsartan, developed by Novartis. The drug has become a cornerstone therapy for patients with heart failure with reduced ejection fraction (HFrEF) due to its superior efficacy over traditional ACE inhibitors.

The key segment within the LCZ 696 API market is the branded synthetic API category. As a complex molecule produced through chemical synthesis, LCZ 696 requires high-end manufacturing capabilities and compliance with stringent regulatory standards. Therapeutically, it belongs to the cardiovascular APIs segment, one of the fastest-growing areas in the pharmaceutical industry due to the global burden of heart diseases and aging populations.

From a geographical standpoint, the United States represents the largest market for LCZ 696 API, attributed to high diagnosis rates of heart failure, favorable reimbursement policies, and early access to novel medications. Europe, particularly countries like Germany, France, and the UK, also shows significant demand. In the Asia-Pacific region, India emerges as a vital market—not only in terms of demand but also as a leading manufacturing hub due to its cost-efficient production and growing expertise in high-value APIs.

Key players dominating the LCZ 696 API market include Novartis as the originator, along with major Indian API manufacturers such as Dr. Reddy’s Laboratories, Lupin Limited, Sun Pharmaceutical Industries, and Aurobindo Pharma, which are involved in supplying the API or offering contract manufacturing services.

The market outlook remains positive, supported by ongoing research in cardiovascular treatments, broader adoption in emerging markets, and increasing emphasis on effective heart failure management.